Cabotegravir GSK744 GSK1265744 GSK-744 CAS: 1051375-10-0

CAS NO: 1051375-10-0
Cabotegravir GSK744 GSK1265744 GSK-744
Chemical Name: Cabotegravir (GSK744, GSK1265744)
Molecular Formula: C19H17F2N3O5
Formula Weight: 405.35
CAS No.: 1051375-10-0
Description Review
Description

Cabotegravir (GSK744, GSK1265744), CAS number 1051375-10-0 is a small molecule compound that is being developed for the prevention and treatment of HIV infections. This molecule has gained significant attention in recent years due to its potential to offer a long-acting antiretroviral therapy that may reduce the frequency of doses.

Chemical Name:

4-([(2,4-difluorophenyl)methyl]carbamoyl)-1,6-dimethyl-2-[(quinolin-3-yl) methyl]-1,4-dihydropyridine-3,5-dicarboxylic acid

Molecular Formula:

C24H23F2N3O4

Molecular Weight:

461.45 g/mol

CAS No:

1051375-10-0

Top 10 Keywords:

  1. HIV prevention
  2. Cabotegravir
  3. GSK744
  4. Long-acting antiretroviral drug
  5. Clinical trials
  6. Quinolin-3-yl-methyl
  7. Pharmacology
  8. HIV treatment
  9. Integrase inhibitor
  10. Pre-exposure prophylaxis

Synonyms:

  1. GSK744LA
  2. Cabotegravir sodium
  3. GSK1265744

Health Benefits:

Cabotegravir has shown promising results in the prevention and treatment of HIV infections. By inhibiting the action of the virus's integrase enzyme, Cabotegravir can reduce the levels of HIV in the body, prevent the progression of the disease, and potentially reduce the frequency of dosing.

Potential Effects:

Cabotegravir inhibits HIV replication by targeting the integrase enzyme, which is responsible for the integration of the virus into the host cell's genome. By blocking the action of this enzyme, Cabotegravir can prevent the virus from replicating and potentially reduce the risk of HIV transmission. It also offers the potential for long-acting antiretroviral therapy, which may improve non-adherence issues seen with standard antiretroviral therapies.

Product Mechanism:

Integrase is an essential enzyme needed for the replication of HIV, which it uses to integrate its genetic material into the host cell's genome. Cabotegravir binds to the active site of the integrase enzyme, preventing its action and blocking the viral replication cycle.

Safety:

Cabotegravir is generally considered safe when used as directed. However, like all drugs, Cabotegravir has the potential to cause side effects. Common side effects may include injection site reactions, fever, and diarrhea. More severe side effects may include liver damage or allergic reactions. Patients taking Cabotegravir should be closely monitored for any signs of adverse reactions.

Side Effects:

As with any drug, the use of Cabotegravir can cause side effects, which may vary from person to person. Common side effects of Cabotegravir may include injection site reactions, fever, and diarrhea. More severe side effects may include liver damage or allergic reactions.

Dosing Information:

Cabotegravir is typically administered via intramuscular injection on a monthly or quarterly basis depending on the indication. Dosing information may vary depending on the patient's age, weight, and overall health, and should be determined by a qualified physician.

Conclusion:

Cabotegravir is a promising antiretroviral therapy that has shown potential benefits in preventing and treating HIV infections. The drug has shown great potential in clinical trials, providing hope for the development of new treatments for these conditions. However, further research is required to determine the long-term effectiveness and safety of Cabotegravir, and patients should always consult with their physician before using any pharmaceutical products.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us